Searched for
PHARMEASY FINANCIAL RESULTS
FirstCry, Slice’s FY26 numbers; Nilekani’s Fundamentum eyes deeptech pushFirstCry parent cut its losses in the March quarter on tightened costs. This and more in today's ETtech Top 5.- Mother's Day Special: How AI, apps are empowering women to manage finances, improve health, build careerWomen are learning to keep pace with the ubiquitous apps and AI, shrugging off dependence on their kids for financial transactions, online ...
- PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%Mumbai-based PharmEasy, operated by API Holdings Limited, reported a net loss of Rs 2,533 crore, an improvement from the Rs 5,212 crore los...
- Mamaearth vs distributors; PharmEasy’s financialsHonasa Consumer, Mamaearth's parent, addressed recent allegations, labelling them as "misinformation." This and more in today’s ETtech Top ...
- Byju’s valuation below $3 billion; company facing challenges: Prosus interim CEOLate last year, Prosus said it had ceased equity accounting of Byju’s as it had lost “significant influence” over the firm after its holdin...
- Goldman may convert part-debt into equity in PharmEasyThe online pharmacy is also in talks to restructure debt terms ahead of rights issue; share sale set to open on September 4
- Goldman may part-convert Pharmeasy debt to equity; P2P lenders look to diversify partnershipsGoldman Sachs is likely to convert some of its loan to online pharmacy PharmEasy into equity. Buoyed by binding commitments from existing i...
- ETtech Explainer: What are down rounds and will they become the norm for Indian startups?A down round is when a privately held firm raises funds at a valuation lower than that ascribed in the previous round.
- Till debt do us part: will startups go the PharmEasy way, and other top tech & startup stories this weekThis week’s ETtech newsbreak on PharmEasy going for a rights issue at a price 90% lower than its peak valuation of $5.6 billion to repay de...
- Startups and their new normal: Funding crunch, disgruntled employees and allegations of fraudWith the global liquidity situation changing, institutional investors were no longer interested in waiting patiently for startups to go hyb...
- PharmEasy devaluation: Thyrocare founder invokes anti-dilution; Flipkart employees to receive esop payoutHappy Friday! Arokiaswamy Velumani, founder of Thyrocare, which was acquired by PharmEasy in 2021, had secured anti-dilution rights when he...
- India’s emerging as next chip-making destination: Ashwini Vaishnaw; VCs reach out to CBDT on angel taxHappy Friday! Union IT minister Ashwini Vaishnaw told ET in an interview that some major players expect India to be the next chip-making de...
- Byju’s lenders scrap talks to recast $1.2B loan; Janus Henderson cuts PharmEasy valuation furtherByju’s woes seem to have no end. The company has suffered a series of setbacks over the last year, including ED raids and valuation markdow...
- Banks, lenders wary as RBI tags C-KYC high risk; Snap bulking up India team in monetisation pushCentralised Know Your Customer (C-KYC) database, which was conceived as a solution to KYC challenges faced by financial institutions, has b...
- PharmEasy prepares Rs 750 crore funding through convertible notesProsus Ventures, Temasek and others participate; online pharmacy reconsidering external fundraise amid funding slowdown
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- Goldman Sachs likely to invest Rs 2,700 crore in PharmEasy parentThe money will predominantly be used to refinance the debt the company had taken to fund its acquisition of diagnostics chain Thyrocare las...
- Demand soars for unlisted stocks of select IPO hopefulsIIFL Securities has sold over Rs 100 crore worth of PharmEasy stock to wealthy individuals at Rs 103 a share. Those shares traded at Rs 78 ...
- PharmEasy’s new backers, Facebook whistleblower revealedPharmEasy is in talks with a clutch of new investors, including two hedge funds, to join its pre-IPO funding round.
- With RIL eyeing Netmeds deal, ePharmacy in for consolidationReliance's yet-to-be announced acquisition of Netmeds for an estimated $120 million is a catalyst for other players such as PharmEasy and M...
Load More
